Edge Therapeutics Inc (EDGE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Edge Therapeutics Inc (EDGE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8181
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, acute neurological conditions. Its lead pipeline products include EG-1962, a proprietary formulation, which is used to treat aneurysmal subarachnoid hemorrhage, is in Phase 3 clinical trials and EG-1964 is in preclinical stage used to prevent recurrent chronic subdural hematoma. The company’s Precise is a proprietary, programmable, biodegradable polymer-based development platform develops products for the treatment of acute neurological conditions. Edge Therapeutics is headquartered in Berkeley Heights, New Jersey, the US.

Edge Therapeutics Inc (EDGE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 10
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 12
Edge Therapeutics Raises USD8 Million in Venture Financing 13
Edge Therapeutics Secures USD3 Million from Hercules Technology 14
Edge Therapeutics Raises US$18 Million In Series C Financing 15
Partnerships 16
Edge Therapeutics Amends its Agreement with Oakwood Labs 16
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 17
Equity Offering 18
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 18
Edge Therapeutics Raises USD92.5 Million in IPO 20
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 22
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 23
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 24
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 25
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 26
Debt Offering 27
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 27
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 28
Edge Therapeutics Inc – Key Competitors 29
Edge Therapeutics Inc – Key Employees 30
Edge Therapeutics Inc – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 01, 2018: Edge Therapeutics Reports Second Quarter 2018 Financial Results 32
May 01, 2018: Edge Therapeutics Announces First Quarter 2018 Financial Results 33
Mar 01, 2018: Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 34
Nov 01, 2017: Edge Therapeutics Reports Third Quarter 2017 Financial Results 35
Aug 01, 2017: Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress 37
May 03, 2017: Edge Therapeutics Q1 net loss increases 38
May 03, 2017: Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress 39
Mar 02, 2017: Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 40
Corporate Communications 41
Sep 19, 2017: Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors 41
Feb 21, 2017: Edge Therapeutics appoints senior vice president of regulatory affairs 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Edge Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Edge Therapeutics Raises USD56 Million in Series C-2 Financing 10
Edge Therapeutics Raises USD16.5 Million in Series C-1 Financing 12
Edge Therapeutics Raises USD8 Million in Venture Financing 13
Edge Therapeutics Secures USD3 Million from Hercules Technology 14
Edge Therapeutics Raises US$18 Million In Series C Financing 15
Edge Therapeutics Amends its Agreement with Oakwood Labs 16
Edge Therapeutics Enters into Research and Discovery Agreement with St. Michael’s Hospital 17
Edge Therapeutics Raises USD18 Million in Private Placement of Shares 18
Edge Therapeutics Raises USD92.5 Million in IPO 20
Edge Therapeutics Raises USD0.15 Million in Private Placement of Preferred Stock 22
Edge Therapeutics Raises USD2.6 Million in Private Placement of Preferred Stock 23
Edge Therapeutics Raises USD3.4 Million in Private Placement of Preferred Stock 24
Edge Therapeutics Raises USD2.5 Million in Private Placement of Preferred Stock 25
Edge Therapeutics Raises USD0.6 Million in Private Placement of Preferred Stock 26
Edge Therapeutics Raises USD0.1 Million in Private Placement of Notes 27
Edge Therapeutics Raises USD0.15 Million in Private Placement of Notes 28
Edge Therapeutics Inc, Key Competitors 29
Edge Therapeutics Inc, Key Employees 30

List of Figures
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Edge Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Edge Therapeutics Inc (EDGE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nippon Flour Mills Co Ltd (2001):企業の財務・戦略的SWOT分析
    Nippon Flour Mills Co Ltd (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • International Games System Co Ltd:企業の戦略・SWOT・財務分析
    International Games System Co Ltd - Strategy, SWOT and Corporate Finance Report Summary International Games System Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • NRG Energy Inc (NRG)-エネルギー分野:企業M&A・提携分析
    Summary NRG Energy, Inc. (NRG) is an integrated energy company that produces, sells and delivers energy, and energy products and services. The company generates power using diverse sources such as coal, natural gas, nuclear, oil, wind and solar. It trades wholesale energy, capacity, fuel and related …
  • Sun BioPharma Inc (SNBP):企業の財務・戦略的SWOT分析
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …
  • Groupama Assurances Mutuelles:企業の戦略・SWOT・財務分析
    Groupama Assurances Mutuelles - Strategy, SWOT and Corporate Finance Report Summary Groupama Assurances Mutuelles - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Pharmascience Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmascience Inc (Pharmascience) is a pharmaceutical company which develops, manufactures and markets generic pharmaceutical products. The company offers generic, prescription, over-the-counter and private label OTC products. It offers drugs in therapeutic areas of anti-inflammatory, cancer …
  • Exact Sciences Corp (EXAS):企業の財務・戦略的SWOT分析
    Exact Sciences Corp (EXAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Pakistan Water and Power Development Authority:電力:M&Aディール及び事業提携情報
    Summary Pakistan Water and Power Development Authority (WAPDA) is a government-owned public authority maintaining power and water in Pakistan. It is responsible for the development of hydel power and water sector projects in Pakistan. The authority plans and executes projects and schemes for the gen …
  • Desitin Arzneimittel GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Desitin Arzneimittel GmbH (Desitin) formerly Desitin Compagnie mbH, is a specialty pharmaceutical company which develops and produces products for the treatment of central nervous system (CNS) related neurological and psychiatric diseases. Its product portfolio includes antiepileptic drugs a …
  • Acuity Brands, Inc.:企業の戦略・SWOT・財務情報
    Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • UMW Holdings Bhd (UMW):石油・ガス:M&Aディール及び事業提携情報
    Summary UMW Holdings Bhd (UMW) is a diversified company. The company operates through its business divisions such as automotive, equipment, manufacturing and engineering, and oil and gas. Its automotive business manufactures, assembles, markets and distributes passenger cars and commercial vehicles. …
  • GEDI Gruppo Editoriale SpA (GEDI):企業の財務・戦略的SWOT分析
    GEDI Gruppo Editoriale SpA (GEDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • WideMed Technologies LTD:医療機器:M&Aディール及び事業提携情報
    Summary WideMed Technologies LTD (WideMed) is a medical device company that develops and manufactures information systems for monitoring, diagnosis and analysis of sleep disorders. The company’s products include Morpheus Modules, Morpheus Hx and Morpheus Ox. Its Morpheus modules are automatic scorin …
  • Repsol Sinopec Resources UK Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Repsol Sinopec Resources UK Ltd (Repsol Sinopec), formerly Talisman Sinopec Energy UK Ltd is an oil and gas company that offers exploration services. The company explores, discovers, and produces oil and gas across the North Sea. It provides operation in floating facilities, offshore platfor …
  • SRI International-医療機器分野:企業M&A・提携分析
    Summary SRI International (SRI) is a research institute which provides commercial research and development programs. It conducts research and development in the areas of biosciences, health and medical systems, chemistry and materials, communications and networks, computing, earth and space, economi …
  • Go-Ahead Group Plc:企業の戦略・SWOT・財務分析
    Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report Summary Go-Ahead Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PT Tempo Scan Pacific Tbk (TSPC):企業の財務・戦略的SWOT分析
    PT Tempo Scan Pacific Tbk (TSPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • CIRCOR Aerospace Products Group:企業の戦略・SWOT・財務情報
    CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report Summary CIRCOR Aerospace Products Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Glencore Plc:企業の戦略・SWOT・財務情報
    Glencore Plc - Strategy, SWOT and Corporate Finance Report Summary Glencore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • BioCorRx Inc (BICX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioCorRx Inc (BioCorRx), formerly Fresh Start Private Management Inc, is a healthcare solution provider. The company provides alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers. It distributes and licenses BioCorRx recovery program, a medication …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆